C4 Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 25 →InsidersNo open-market buys. 1 insider sold $22,200 in 1 sale, with no 10b5-1 plan named.→HoldersMorgan Stanley 7.2%Ra 6.5%BlackRock 6.4%→Financing →PeersClosest companies: BDTX, RLAY, CGEM→
From the filings
Figures
- Revenue
- $35.0Mlast 12 months
- Net income
- −$101.4Mlast 12 months
- Operating cash flow
- −$95.4Mlast 12 months
- Cash and equivalents
- $78.6Mat the last balance sheet
- Shares outstanding
- 122.9M shareson issue